A clinical trial to compare the effects of Iris Versicolor over Individualized Homoeopathic Medicines in patients suffering from Migraine

Evaluating the effectiveness of Individualized Homoeopathic Medicines vs Iris Versicolor in treatment of Migraine: A randomised controlled clinical trial - NIL

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/11/077035

Enrollment

Registered

2024-11-19

Start date

Unknown

Completion date

Unknown

Last updated

2024-12-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: G43- Migraine

Interventions

Intervention1: Iris Versicolor: Iris Versicolor will be administered in centesimal potencies, selected according to homoeopathic principles. The dose and repetition will be adjusted as per the require

Eligibility

Inclusion criteria

Inclusion criteria: 1.Both sexes of age group 18-60 years, irrespective of their race, caste, religion and socioeconomic status. 2.Patients presenting with symptoms of migraine according to International Classification of Headache Disorder 3rd edition (ICHD-III).

Exclusion criteria

Exclusion criteria: 1. Patients suffering with any cause of secondary headache like trauma, metabolic or vascular disorders, non-vascular intracranial lesions, abuse of alcohol or other psychoactive substances. 2. Pregnant and lactating mothers. 3. Migraine patients suffering from any life-threatening complication. 4. Patients with history of cerebral-vascular accident, convulsions, severe coronary disease, uncontrolled hypertension, and malignancy. 5. Patients with psychiatric comorbidities. 6. Unwilling to take part and not giving consent to join the study or unable to read the patient information sheet. Patients unable to comply with study protocol.

Design outcomes

Primary

Measure	Time frame
To compare the effectiveness of Individualized Homoeopathic Medicines vs Iris versicolor in reducing the intensity(VAS) and frequency(attacks per month) of Migraine among the participants. Timepoint: The Visual Analog Scale (VAS) for pain will be measured at baseline and then at every 2 weeks, till 6 months(24th week) of treatment while the frequency of migraine attacks will be recorded at baseline and then at every 4 weeks, till 6 months(24th week) of treatment.	—

Measure

Time frame

To compare the effectiveness of Individualized Homoeopathic Medicines vs Iris versicolor in reducing the intensity(VAS) and frequency(attacks per month) of Migraine among the participants. Timepoint: The Visual Analog Scale (VAS) for pain will be measured at baseline and then at every 2 weeks, till 6 months(24th week) of treatment while the frequency of migraine attacks will be recorded at baseline and then at every 4 weeks, till 6 months(24th week) of treatment.

—

Secondary

Measure	Time frame
To evaluate the effectiveness of Individualized Homoeopathic Medicines compared to Iris versicolor on migraine-related disability using the Migraine Disability Assessment (MIDAS) score as the outcome measure.Timepoint: The Migraine Disability Assessment (MIDAS) will be evaluated twice in this study. First at baseline & then after six months(24th week) of treatment.	—

Countries

India

Contacts

Public ContactDr Manisha Gairola

Dr. B.R. Sur Homoeopathic Medical College, Hospital and Research Centre

drrajivh@yahoo.co.in9868393285

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026